Literature DB >> 15385362

The procoagulatory effects of delta-9-tetrahydrocannabinol in human platelets.

Engelbert Deusch1, Hans Georg Kress, Birgit Kraft, Sibylle A Kozek-Langenecker.   

Abstract

Delta-9-tetrahydrocannabinol (THC) is increasingly used for the long-term treatment of nausea, vomiting, cachexia, and chronic pain. Recent reports, however, have indicated an increased risk of myocardial infarction and thromboangiitis obliterans after THC intake. Blood platelets have an essential role in the pathogenesis of these two diseases, but it is unclear whether platelets are potential target cells for cannabinoids. We investigated the effects of THC on human platelets and the expression of cannabinoid receptors on their cell membranes in this in vitro study. The effects of THC (final concentrations 10(-7) to 10(-5) M) on the expression of activated platelet fibrinogen receptor (glycoprotein IIb-IIIa) and P selectin were characterized by flow cytometry. Western blotting was performed with platelet membrane preparations to determine the surface expression of cannabinoid receptors on human platelets. THC increased the expression of glycoprotein IIb-IIIa and P selectin on human platelets in a concentration-dependent manner. The two known cannabinoid receptors (CB(1) and CB(2)) were both detected on the cell membrane of human platelets. Our functional results may suggest a receptor-dependent pathway of THC-induced platelet activation. However, further in vivo studies are warranted to evaluate the role of cannabinoid receptors in mediating the demonstrated procoagulatory effect of THC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15385362     DOI: 10.1213/01.ANE.0000131505.03006.74

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  38 in total

1.  Myocardial infarction following cannabis induced coronary vasospasm.

Authors:  Mudalige Don Vajira Malin Gunawardena; Senaka Rajapakse; Jagath Herath; Naomali Amarasena
Journal:  BMJ Case Rep       Date:  2014-11-12

Review 2.  Endocannabinoids and the haematological system.

Authors:  M D Randall
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

3.  Cannabinoid Receptor-2 Regulates Embryonic Hematopoietic Stem Cell Development via Prostaglandin E2 and P-Selectin Activity.

Authors:  Virginie Esain; Wanda Kwan; Kelli J Carroll; Mauricio Cortes; Sarah Y Liu; Gregory M Frechette; Lea M V Sheward; Sahar Nissim; Wolfram Goessling; Trista E North
Journal:  Stem Cells       Date:  2015-05-26       Impact factor: 6.277

4.  Cannabis and Cannabinoid Biology in Stroke.

Authors:  Sang-Ho Choi; Yongshan Mou; Afonso C Silva
Journal:  Stroke       Date:  2019-08-01       Impact factor: 7.914

Review 5.  The Impact of Perioperative Cannabis Use: A Narrative Scoping Review.

Authors:  Karim S Ladha; Varuna Manoo; Ali-Faizan Virji; John G Hanlon; Alexander Mclaren-Blades; Akash Goel; Duminda N Wijeysundera; Lakshmi P Kotra; Carlos Ibarra; Marina Englesakis; Hance Clarke
Journal:  Cannabis Cannabinoid Res       Date:  2019-12-06

6.  Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion.

Authors:  Sarah K Walsh; Claire Y Hepburn; Kathleen A Kane; Cherry L Wainwright
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 7.  Role of cannabis in cardiovascular disorders.

Authors:  Hemant Goyal; Hamza H Awad; Jalal K Ghali
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

8.  Acute myocardial infarction triggered by use of synthetic cannabis.

Authors:  Brooke Mills; Emma Dishner; Carlos E Velasco
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-03-12

Review 9.  The emerging role of the endocannabinoid system in cardiovascular disease.

Authors:  Pál Pacher; Sabine Steffens
Journal:  Semin Immunopathol       Date:  2009-04-09       Impact factor: 9.623

Review 10.  Cannabinoid receptors in acute and chronic complications of atherosclerosis.

Authors:  F Mach; F Montecucco; S Steffens
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.